PDF(Pubmed)
Abstract：
Nivolumab, an investigational monoclonal antibody targeting a specific immune pathway, has shown promise in treating various autoimmune diseases. However, like other immunomodulatory agents, it has potential side effects. This case report describes a rare adverse event of nivolumab-induced diabetic ketoacidosis (DKA) in a patient with a history of adrenal insufficiency secondary to nivolumab. The patient presented with symptoms of hyperglycemia, metabolic acidosis, and ketosis after receiving nivolumab therapy for 12 cycles. Prompt recognition and management of nivolumab-induced DKA are crucial to prevent complications and ensure patient safety.
摘要：
Nivolumab,一种针对特定免疫途径的研究性单克隆抗体，在治疗各种自身免疫性疾病方面显示出希望。然而,像其他免疫调节剂一样，它有潜在的副作用。该病例报告描述了在具有继发于nivolumab的肾上腺功能不全病史的患者中，nivolumab诱导的糖尿病酮症酸中毒（DKA）的罕见不良事件。患者出现高血糖症状，代谢性酸中毒,和酮症后接受纳武单抗治疗12个周期。及时识别和管理nivolumab诱导的DKA对于预防并发症和确保患者安全至关重要。
